The fact that FGL-1 levels in the blood of cancer patients correlates with poor prognosis and resistance to anti-PD-1/B7-H1 therapy suggests FGL-1 as a major contributor to LAG-3 immunoregulation [178]. The gene discussed is CD274; the disease is cancer.